Tag Archive for: Phase 1 data

STORM Therapeutics to present promising Phase 1 sarcoma data demonstrating activity of first‑in‑class METTL3 inhibitor STC‑15 at ASCO 2026

/in

Subset analysis shows early clinical activity supported by biomarker evidence of targeting cancer stem cell pathways driving tumor growth and progression 22 May 2026, Cambridge, UK: STORM Therapeutics Ltd. (STORM), the clinical stage company targeting RNA modifications to reprogram cells and develop novel cancer therapies, today announces that a subset analysis of sarcoma patients enrolled […]

Read more

Freya Biosciences announces positive Phase 1 first-in-human data with FB301 for IVF-related embryo implantation failure

/in

FB301 was safe and well tolerated in healthy female subjects, with all primary and secondary endpoints met Clinically meaningful microbiome modulation observed, including significant improvement up to 6-month follow-up Results support progression into Phase 2, with FDA IND clearance granted in the US and CTA approved in Germany Copenhagen, Denmark and Boston, Massachusetts, 16 April […]

Read more

DeuterOncology to Present Promising Phase I DO-2 MET Kinase Inhibitor Data at WCLC 2025

/in

DO-2 is a best-in-class MET kinase inhibitor that has completed enrollment in a Phase 1 dose escalation study Tumor shrinkage was observed in 100% of MET exon 14 skip NSCLC patients without additional oncogenic drivers, at doses that achieved preclinically defined thresholds DO-2 has a very good safety profile with minimal peripheral oedema and clean […]

Read more
© Optimum Strategic Communications.